CRISPR decodes the RNA regulatory network in prostate cancer: A review from mechanisms to precision therapeutics.

Song Zhu, Gao Ni, Pinjie Zhang, Yili Yang, Hongxiang He, Junfeng Jiang, Zhang Li

Abstract readReview

In one paragraph

Review in Non-coding RNA research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Song ZhuSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, China.

Gao NiDepartment of Histology and Embryology, College of Basic Medicine, Naval Medical University, Shanghai 200433, China.

Pinjie ZhangSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, China.

Yili YangSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, China.

Hongxiang HeSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, China.

Junfeng JiangSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, China.

Zhang LiDepartment of Pathogen Biology, Naval Medical University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) remains one of the most prevalent and lethal malignancies in men worldwide. The pronounced heterogeneity and therapeutic resistance of PCa underscore the critical need to decipher its RNA regulatory network for advancing precision medicine. This review systematically outlines the cutting-edge applications of CRISPR technology in studying the RNA regulatory network of PCa. We highlight the CRISPR systems as a powerful tool for functional decoding, target screening, ultrasensitive diagnostics, and precision intervention, emphasizing their pivotal role in elucidating the functional mechanisms of mRNA, miRNA, circRNA, lncRNA, eRNA, and m

Indexed as

CRISPR technologyNon-coding RNAPrecision medicineProstate cancerRNA regulatory network

Identifiers

PMID42253611

DOI10.1016/j.ncrna.2026.05.001

PMCPMC13240780

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.